Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Not Applicable

Recruiting

• Conditions: Breast Cancer, Familial Male; Radiotherapy; Complications; Chemotherapeutic Toxicity; Immune Checkpoint Inhibitor; CDK4/6 Inhibitor; Trastuzumab; Pertuzumab; PARP Inhibitor

• Registration Number: NCT06197581
• Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-5
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 148

Inclusion Criteria

Inclusion Criteria:<br><br>ECOG 0-2. Aged 18-70 years old. Pathologically diagnosed as breast cancer. Need to<br>receive radiotherapy according to guidelines. Radiotherapy target volume included chest<br>wall/breast with or without lymph node regions.<br><br>Need to receive one of the following therapies according to guidelines, capetabine,<br>CDK4/6 inhibitor, PARP inhibitor , ICIs , HER2 inhibitors.<br><br>Exclusion Criteria:<br><br>Male breast cancer. Allergy to the upper medicines before. Will receive trastuzumab alone<br>during and/or after radiotherapy. With severe other disease.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Grade 3 adverse events

Secondary Outcome Measures

Name	Time	Method
Adverse events with any grade